MarketBeat
06 Nov 2026, 08:15 UTC · 1h ago
What iRhythm Technologies (IRTC) Said on Its Q3 Earnings Call
Impact · against what's priced in
The slight raise in 2026 guidance provides minor support but confirms that growth is decelerating compared to the near-30% CAGR the market requires for current valuations. The delay of the Zio MCT product and the Zio AT revenue headwind further undermine the growth trajectory needed to close the gap between the current price and analyst targets.
- IRTC−0.30
Challenges what's priced in
- The price assumes
Sustained high-20s revenue growth
While the company raised 2026 revenue guidance to $890M-$895M, this represents 19-20% growth, which is significantly below the 29.8% CAGR the market currently requires to justify its valuation.
What IRTC's price assumes · Sep 24
